These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 34050373)
21. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report. Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria. Agarwal S; Simon AR; Goel V; Habtemariam BA; Clausen VA; Kim JB; Robbie GJ Clin Pharmacol Ther; 2020 Jul; 108(1):63-72. PubMed ID: 31994716 [TBL] [Abstract][Full Text] [Related]
23. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365 [TBL] [Abstract][Full Text] [Related]
24. Preliminary report: hyperhomocysteinemia in patients with acute intermittent porphyria. To-Figueras J; Lopez RM; Deulofeu R; Herrero C Metabolism; 2010 Dec; 59(12):1809-10. PubMed ID: 20627200 [TBL] [Abstract][Full Text] [Related]
25. Elevated homocysteine is negatively correlated with plasma cystathionine β-synthase activity in givosiran-treated patients. Keibler MA; Sridharan GV; Sweetser MT; Ticau S JIMD Rep; 2024 Jul; 65(4):262-271. PubMed ID: 38974609 [TBL] [Abstract][Full Text] [Related]
26. Case report of a complicated neurologically manifesting acute porphyria treated successfully with Givosiran. Steinberg T; Kilic M; Fuchs K; Hanyk K; Linker RA; Schlachetzki F; Neumann B J Neurol Sci; 2021 Mar; 422():117334. PubMed ID: 33581419 [No Abstract] [Full Text] [Related]
27. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP). Massachi S; Epstein J; Hurd J; Bonkovsky HL J Med Econ; 2020 Dec; 23(12):1441-1449. PubMed ID: 33043761 [TBL] [Abstract][Full Text] [Related]
28. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs. Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795 [TBL] [Abstract][Full Text] [Related]
29. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver. Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020 [TBL] [Abstract][Full Text] [Related]
30. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria. Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115 [TBL] [Abstract][Full Text] [Related]
31. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin. Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206 [TBL] [Abstract][Full Text] [Related]
32. Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks. Puy H; Deybach JC; Baudry P; Callebert J; Touitou Y; Nordmann Y Life Sci; 1993; 53(8):621-7. PubMed ID: 8350677 [TBL] [Abstract][Full Text] [Related]
33. Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias. Badawy AA Med Hypotheses; 2019 Oct; 131():109314. PubMed ID: 31443750 [TBL] [Abstract][Full Text] [Related]
34. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197 [TBL] [Abstract][Full Text] [Related]
35. Givosiran for the treatment of acute hepatic porphyria. Ricci A; Ventura P Expert Rev Clin Pharmacol; 2022 Apr; 15(4):383-393. PubMed ID: 35531651 [TBL] [Abstract][Full Text] [Related]
36. Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias. Schneider-Yin X; van Tuyll van Serooskerken AM; Siegesmund M; Went P; Barman-Aksözen J; Bladergroen RS; Komminoth P; Cloots RH; Winnepenninckx VJ; zur Hausen A; Weber M; Driessen A; Poblete-Gutiérrez P; Bauer P; Schroeder C; van Geel M; Minder EI; Frank J J Hepatol; 2015 Mar; 62(3):734-8. PubMed ID: 25445397 [TBL] [Abstract][Full Text] [Related]
37. Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP. Linenberger M; Fertrin KY Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):400-410. PubMed ID: 33275677 [TBL] [Abstract][Full Text] [Related]
38. Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations. Clavero S; Bishop DF; Haskins ME; Giger U; Kauppinen R; Desnick RJ Hum Mol Genet; 2010 Feb; 19(4):584-96. PubMed ID: 19934113 [TBL] [Abstract][Full Text] [Related]
39. Porphyric neuropathy: prevention of progression using haeme-arginate. Muthane UB; Vengamma B; Bharathi KC; Mamatha P J Intern Med; 1993 Dec; 234(6):611-3. PubMed ID: 8258754 [TBL] [Abstract][Full Text] [Related]